Table 3.

Factors associated with irAE at ICU discharge in patients receiving ICI and admitted to the ICU (n = 110 patients)

	Univariate analysis		Multivariate analysis with variables clinically relevant		Multivariate analysis with backward selection
	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Gender: female vs. male	1.04 (0.46–2.32)	0.93	0.93 (0.34–2.53)	0.89
Age (per year)	1.02 (0.98–1.06)	0.33	1.01 (0.99–1.10)	0.15
CCI (per point)	0.91 (0.79–1.06)	0.23	0.94 (0.78–1.14)	0.54
ECOG-PS		0.005		0.0005		0.003
2–3	1		1		1
1	3.40 (1.27–8.99)		8.43 (2.39–29.72)		3.66 (1.33–10.03)
0	5.35 (1.89–15.17)		11.23 (2.87–43.97)		6.34 (2.13–18.90)
Type of cancer		0.61		0.63
Lung	1		1
Melanoma	2.05 (0.73–5.82)		0.67 (0.55–12.90)
Bladder	0.41 (0.04–3.86)		0.31 (0.01–7.14)
Kidney	0.82 (0.07–9.48)		2.47 (0.16–37.43)
Other	1.10 (0.28–4.22)		1.08 (0.187–6.17)
Metastatic vs. localized disease	0.86 (0.33–2.26)	0.77		0.65
Cancer status		0.22		0.14
Controlled	1		1
In progression	0.44 (0.17–1.14)		0.30 (0.08–1.15)
Not evaluated	0.61 (0.25–1.51)		1.22 (0.37–4.04)
Reason for ICU admission		0.27		0.12
Respiratory	1		1
Colitis	1.02 (0.32–3.27)		0.57 ( 0.12–2.74)
Cardiovascular	0.11 (0.01–0.92)		0.03 (0.003–0.043)
Metabolic	1.63 (0.45–5.88)		1.00 (0.17–6.02)
Neurologic	1.36 (0.26–7.23)		0.35 (0.03–3.69)
Line of anticancer treatment: > 2 vs. 1–2	1.61 (0.56–4.67)	0.38	2.06 (0.46–9.20)	0.35
History of immune toxicity: yes vs. no	2.61 (1.04–6.59)	0.04	4.13 (0.88–19.50)	0.07	3.28 (1.19–9.01)	0.02
Time from first ICI infusion (per month)	1.02 (0.97–1.07)	0.43	0.94 (0.87–1.01)	0.08

CCI Charlson Comorbidity Index, CI confidence interval, ECOG Eastern Cooperative Oncology Group, ICI immune checkpoint inhibitor, ICU intensive care unit, PS performance status